vs
ImmunityBio, Inc.（IBRX）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是ImmunityBio, Inc.的1.5倍（$57.1M vs $38.3M），REGIS CORP净利率更高（0.8% vs -161.8%，领先162.6%），ImmunityBio, Inc.同比增速更快（407.0% vs 22.3%），REGIS CORP自由现金流更多（$891.0K vs $-71.3M）
ImmunityBio, Inc.是一家处于临床阶段的生物技术企业，专注开发针对多种癌症及传染性疾病的下一代免疫疗法与候选疫苗，核心研发方向涵盖细胞疗法、抗体药物及靶向疫苗平台，主要运营市场位于美国。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
IBRX vs RGS — 直观对比
营收规模更大
RGS
是对方的1.5倍
$38.3M
营收增速更快
IBRX
高出384.7%
22.3%
净利率更高
RGS
高出162.6%
-161.8%
自由现金流更多
RGS
多$72.2M
$-71.3M
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $57.1M |
| 净利润 | $-61.9M | $456.0K |
| 毛利率 | 99.0% | — |
| 营业利润率 | -169.0% | 10.8% |
| 净利率 | -161.8% | 0.8% |
| 营收同比 | 407.0% | 22.3% |
| 净利润同比 | -4.7% | -94.0% |
| 每股收益（稀释后） | $-0.06 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBRXRGS
| Q4 25 | $38.3M | $57.1M | ||
| Q3 25 | $32.1M | $59.0M | ||
| Q2 25 | $26.4M | $60.4M | ||
| Q1 25 | $16.5M | $57.0M | ||
| Q4 24 | $7.6M | $46.7M | ||
| Q3 24 | $6.1M | $46.1M | ||
| Q2 24 | — | $49.4M | ||
| Q1 24 | — | $49.2M |
净利润IBRXRGS
| Q4 25 | $-61.9M | $456.0K | ||
| Q3 25 | $-67.3M | $1.4M | ||
| Q2 25 | $-92.6M | $116.5M | ||
| Q1 25 | $-129.6M | $250.0K | ||
| Q4 24 | $-59.2M | $7.6M | ||
| Q3 24 | $-85.7M | $-853.0K | ||
| Q2 24 | — | $91.2M | ||
| Q1 24 | — | $-2.3M |
毛利率IBRXRGS
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率IBRXRGS
| Q4 25 | -169.0% | 10.8% | ||
| Q3 25 | -173.5% | 10.0% | ||
| Q2 25 | -269.8% | 12.1% | ||
| Q1 25 | -390.1% | 8.8% | ||
| Q4 24 | -919.0% | 11.8% | ||
| Q3 24 | -1314.3% | 4.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 8.3% |
净利率IBRXRGS
| Q4 25 | -161.8% | 0.8% | ||
| Q3 25 | -209.8% | 2.3% | ||
| Q2 25 | -350.3% | 192.9% | ||
| Q1 25 | -784.9% | 0.4% | ||
| Q4 24 | -783.4% | 16.4% | ||
| Q3 24 | -1404.0% | -1.9% | ||
| Q2 24 | — | 184.7% | ||
| Q1 24 | — | -4.7% |
每股收益（稀释后）IBRXRGS
| Q4 25 | $-0.06 | $0.16 | ||
| Q3 25 | $-0.07 | $0.49 | ||
| Q2 25 | $-0.10 | $43.67 | ||
| Q1 25 | $-0.15 | $0.08 | ||
| Q4 24 | $-0.08 | $2.71 | ||
| Q3 24 | $-0.14 | $-0.36 | ||
| Q2 24 | — | $38.40 | ||
| Q1 24 | — | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $242.8M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $-500.5M | $188.7M |
| 总资产 | $501.9M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资IBRXRGS
| Q4 25 | $242.8M | $18.4M | ||
| Q3 25 | $257.8M | $16.6M | ||
| Q2 25 | $153.7M | $17.0M | ||
| Q1 25 | $61.6M | $13.3M | ||
| Q4 24 | $149.8M | $10.2M | ||
| Q3 24 | $130.4M | $6.3M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.9M |
总债务IBRXRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益IBRXRGS
| Q4 25 | $-500.5M | $188.7M | ||
| Q3 25 | $-524.3M | $187.6M | ||
| Q2 25 | $-570.7M | $185.6M | ||
| Q1 25 | $-591.4M | $68.6M | ||
| Q4 24 | $-489.1M | $66.7M | ||
| Q3 24 | $-745.1M | $56.4M | ||
| Q2 24 | — | $56.8M | ||
| Q1 24 | — | $-35.8M |
总资产IBRXRGS
| Q4 25 | $501.9M | $588.3M | ||
| Q3 25 | $519.0M | $592.1M | ||
| Q2 25 | $402.1M | $599.0M | ||
| Q1 25 | $303.8M | $511.2M | ||
| Q4 24 | $382.9M | $530.1M | ||
| Q3 24 | $364.6M | $508.9M | ||
| Q2 24 | — | $530.5M | ||
| Q1 24 | — | $543.7M |
负债/权益比IBRXRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.4M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $-71.3M | $891.0K |
| 自由现金流率自由现金流/营收 | -186.2% | 1.6% |
| 资本支出强度资本支出/营收 | 2.4% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-308.8M | $14.9M |
8季度趋势，按日历期对齐
经营现金流IBRXRGS
| Q4 25 | $-70.4M | $1.7M | ||
| Q3 25 | $-68.9M | $2.3M | ||
| Q2 25 | $-79.7M | $6.8M | ||
| Q1 25 | $-85.9M | $6.2M | ||
| Q4 24 | $-85.1M | $2.1M | ||
| Q3 24 | $-98.8M | $-1.3M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-277.0K |
自由现金流IBRXRGS
| Q4 25 | $-71.3M | $891.0K | ||
| Q3 25 | $-69.6M | $1.9M | ||
| Q2 25 | $-80.8M | $6.2M | ||
| Q1 25 | $-87.0M | $5.9M | ||
| Q4 24 | $-87.3M | $1.7M | ||
| Q3 24 | $-101.6M | $-1.4M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-326.0K |
自由现金流率IBRXRGS
| Q4 25 | -186.2% | 1.6% | ||
| Q3 25 | -217.2% | 3.2% | ||
| Q2 25 | -305.9% | 10.3% | ||
| Q1 25 | -526.9% | 10.3% | ||
| Q4 24 | -1155.4% | 3.6% | ||
| Q3 24 | -1663.2% | -3.0% | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | -0.7% |
资本支出强度IBRXRGS
| Q4 25 | 2.4% | 1.4% | ||
| Q3 25 | 2.3% | 0.7% | ||
| Q2 25 | 4.1% | 0.9% | ||
| Q1 25 | 6.8% | 0.6% | ||
| Q4 24 | 28.0% | 0.9% | ||
| Q3 24 | 45.7% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
现金转化率IBRXRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBRX
暂无分部数据
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
